SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 693.35-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (2547)10/25/2018 4:30:00 PM
From: Miljenko Zuanic   of 3559
 
Model: hhs.gov
<Here is how the model will work:
Today’s system: Medicare sets payments for physician-administered drugs at the average sales price in the U.S. market—plus a price-based add-on fee.New model: Medicare sets the payment for these drugs at a Target Price, based on the discounts drug companies give other countries.With the model fully implemented, total payment for these drugs will drop by 30 percent.The Target Price is 126 percent of the average price other countries pay for the drug.The model incorporates a new, larger add-on fee for hospitals and doctors that is independent of prices.>

So, what power REGN have to increase Eylea price in, for instance, Canada, in next few months?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News